May 27, 2025 BRIDGEWATER, N.J. — Amneal Pharmaceuticals has launched Exenatide 1.2 mL and 2.4 mL prefilled pen injection, an AP-rated generic equivalent for BYETTA. Exenatide is a glucagon-like peptide-1 (GLP-1) agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Availability of this generic alternative is significant as the brand was recently discontinued*. Prescribers and patients now have access to exenatide therapy again.
Both the 5 mcg (1.2 mL) and 10 mcg (2.4 mL) size pen deliver 60 subcutaneous doses. Needles are not included, and pens should be stored in the refrigerator until first use at which time they can be kept at room temperature not to exceed 77°F (25°C). A website featuring instructions for use and other information is live at AmnealExenatide.com.
Patients taking exenatide have experienced changes in kidney function, low blood sugar, and inflammation of the pancreas while using exenatide. The most common side effects include nausea, low blood sugar, vomiting, diarrhea, feeling jittery, dizziness, headache, indigestion, constipation, and weakness. For complete prescribing information, please refer to the package insert available here.
Exenatide Injection is available for sale now through most wholesalers. Contact CustomerRelations@amneal.com with questions about direct purchasing options.
